REALITY Trial Investigators’ Expectations May Have Been Unrealistic – JAMA
This article was originally published in The Gray Sheet
Executive Summary
Investigators in the Johnson & Johnson-sponsored REALITY drug-eluting stent trial should not have expected large differences in outcomes between J&J's Cypher and Boston Scientific's Taxus, according to an editorial in the Feb. 22 issue of the Journal of the American Medical Association